<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>WHO criteria: chronic eosinophilic leukemia and hypereosinophilic syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">WHO criteria: chronic eosinophilic leukemia and hypereosinophilic syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">WHO criteria: chronic eosinophilic leukemia and hypereosinophilic syndrome</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Required </td> </tr> <tr> <td>Persistent peripheral blood eosinophilia (≥1500/microL)</td> </tr> <tr> <td>Increased numbers of bone marrow eosinophils</td> </tr> <tr> <td>Myeloblasts &lt;20 percent in peripheral blood or bone marrow</td> </tr> <tr> <td class="subtitle1_single">Conditions to be excluded </td> </tr> <tr> <td class="subtitle2_single">Reactive eosinophilia </td> </tr> <tr> <td class="indent1">Allergy </td> </tr> <tr> <td class="indent1">Parasitic diseases </td> </tr> <tr> <td class="indent1">Infectious diseases </td> </tr> <tr> <td class="indent1">Pulmonary disease (eg, hypersensitivity pneumonia, Loeffler's pneumonia) </td> </tr> <tr> <td class="indent1">Collagen vascular disorders </td> </tr> <tr> <td class="subtitle2_single">Neoplastic disorders with secondary reactive eosinophilia </td> </tr> <tr> <td class="indent1">T cell lymphomas (eg, mycosis fungoides, Sézary syndrome) </td> </tr> <tr> <td class="indent1">Hodgkin lymphoma</td> </tr> <tr> <td class="indent1">Acute lymphoblastic leukemia </td> </tr> <tr> <td class="indent1">Mastocytosis </td> </tr> <tr> <td class="subtitle2_single">Neoplastic disorders in which eosinophils are part of the neoplastic clone </td> </tr> <tr> <td class="indent1">Chronic myeloid leukemia (Ph1 + or BCR/ABL positive) </td> </tr> <tr> <td class="indent1">Acute myeloid leukemia [eg, FAB M4Eo with inv(16), t(16;16)(p13;q22)] </td> </tr> <tr> <td class="indent1">Other myeloproliferative disorders (eg, polycythemia vera, essential thrombocytosis, chronic idiopathic myelofibrosis) </td> </tr> <tr> <td class="subtitle2_single">T cell population with aberrant phenotype and abnormal cytokine production </td> </tr> <tr> <td class="subtitle1_single">Diagnosis </td> </tr> <tr> <td class="subtitle2_single">Hypereosinophilic syndrome: </td> </tr> <tr> <td class="indent1">This diagnosis is made if there is no demonstrable disease that could cause the eosinophilia, no abnormal T cell population, and no evidence for a clonal myeloid malignancy. </td> </tr> <tr> <td class="subtitle2_single">Chronic eosinophilic leukemia: </td> </tr> <tr> <td class="indent1">This diagnosis is made if all of the above exclusions have been met and if the myeloid cells demonstrate a clonal chromosomal abnormality, or are shown to be clonal by other means, or blast cells are present in the peripheral blood (&gt; 2 percent) or are increased in the bone marrow (&gt;5 to &lt;19 percent of nucleated cells). </td> </tr> </tbody></table></div><div class="graphic_reference">Adapted from: Bain B, et al. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2001. p.49. Permission granted from Harris NL and Vardiman JW.</div><div id="graphicVersion">Graphic 54770 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
